Orally administered CCR2 selective inhibitor CCX872-b clinical trial in pancreatic cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.4_suppl.276
Abstract: 276Background: CCR2 inhibition decreases tumor-associated macrophages and Treg cells, and increases CD8+ and CD4+ T cells in pancreatic tumors. Single oral doses of 150 mg CCX872-B were well tolerated in patients with pancreatic cancer. The… read more here.
Keywords: ccx872; administered ccr2; pancreatic cancer; ecog score ... See more keywords